Physician profile
Sheetal Mehta
NPI 1841418035
$1,190.35
in general payments reported to CMS, 2019-2025
13 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2021: $16.63 · 2022: $50.04 · 2023: $25.01 · 2024: $122 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.42 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $250.19 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $224.87 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $180.07 | 2019 | |
| Pfizer INC. | $100.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $100.21 | 2024-2025 | Dupixent |
| Genzyme Corporation | $93.32 | 2025 | |
| Abbvie INC. | $72.09 | 2022-2024 | |
| Incyte Corporation | $51.95 | 2023-2024 | Opzelura |
| Almirall LLC | $32.11 | 2025 | Seysara |
| Dermavant Sciences, INC. | $24.57 | 2024 | Vtama |
| Lilly USA, LLC | $24.15 | 2025 | Taltz, Ebglyss |
| Merz North America, INC. | $19.67 | 2019 | |
| Misonix INC | $16.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.